跳至主要内容
临床试验/NCT01262118
NCT01262118已完成1 期

An Exploratory Phase 1, Fixed Sequence, Open-Label Study To Assess The Effects Of CP-690,550 On The Kinetics Of Cholesterol Flux Through The High Density Lipoprotein/Reverse Cholesterol Transport Pathway In Patients With Active Rheumatoid Arthritis

Pfizer1 个研究点 分布在 1 个国家目标入组 69 人开始时间: 2011年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Pfizer
入组人数
69
试验地点
1
主要终点
High-density Lipoprotein Cholesterol (HDL-C) Concentration at Baseline

研究概览

简要总结

The purpose of study is to explore the effect of CP-690,550 (tasocitinib) on cholesterol metabolism in patients with active rheumatoid arthritis (RA).

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males or females, 18 years of age or older with active rheumatoid arthritis; Or male and female healthy volunteers 18 years of age and older

排除标准

  • Pregnant or lactating women
  • Clinically significant systemic disease (other than RA for RA arm)
  • Use of lipid-regulating agents

研究组 & 干预措施

CP-690,550 (tasocitinib) 10 mg twice daily (BID)

Experimental

干预措施: CP-690,550 (tasocitinib) (Drug)

结局指标

主要结局

High-density Lipoprotein Cholesterol (HDL-C) Concentration at Baseline

时间窗: Baseline

Blood level of HDL-C was measured following a 12-hours fasting.

High-density Lipoprotein Cholesterol (HDL-C) Concentration at Week 6

时间窗: Week 6

Blood level of HDL-C was measured following a 12-hours fasting.

Cholesterol Ester Production Rate at Baseline

时间窗: Baseline

Cholesterol ester production rate was calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program.

Cholesterol Ester Production Rate at Week 6

时间窗: Week 6

Cholesterol ester production rate was calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program.

次要结局

  • Low-density Lipoprotein Cholesterol (LDL-C) and Total Cholesterol Concentration(Baseline, Week 6)
  • Cholesterol Ester Fractional Catabolic Rate(Baseline, Week 6)
  • Low-density Lipoprotein Associated With Apolipoprotein B (LDL-apoB) Production Rate(Baseline, Week 6)
  • Low-density Lipoprotein Associated With Apolipoprotein B (LDL-apoB) Fractional Catabolic Rate(Baseline, Week 6)
  • High-density Lipoprotein Associated With Apolipoprotein A1 (HDL-apoA1) Production Rate(Baseline, Week 6)
  • High-density Lipoprotein Associated With Apolipoprotein A1 (HDL-apoA1) Fractional Catabolic Rate(Baseline, Week 6)
  • Cholesterol Efflux Rate(Baseline, Week 6)

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验